Company Overview
Aethlon Medical, Inc. operates as a medical therapeutic company focused on the United States, where it develops novel immunotherapeutic devices designed to treat cancer and viral infections. The company functions within the Healthcare sector, specifically the Medical Devices industry, a classification that signifies its engagement in manufacturing equipment used for clinical diagnostics or therapeutic procedures. At present, the company's scale is defined by a market capitalization of $3.37M, a total cash position of $6.96M, and an employee count of 9. The current market cap and revenue figures, which are not available for reporting, indicate that the company maintains a very small market footprint relative to established large-cap medical device peers. This limited scale suggests the organization is likely in an early-stage development phase, relying on a minimal workforce to advance its clinical-stage Hemopurifier device intended for cancer applications and life-threatening viral infections.
Financial Health
The company reports a Net Income of $-11,522,096 over the trailing twelve months, while its EBITDA stands at $-7,007,023 and Revenue is not available for reporting. The significant gap between the reported revenue (which cannot be quantified here) and the substantial Net Loss reveals a cost structure where operating expenses heavily outweigh any generated revenue, a common characteristic for firms in the clinical development stage of the device lifecycle. Free Cash Flow is reported at $-4,544,826, indicating that the company is currently burning cash to fund its operations and research rather than generating liquidity from business activities. This negative cash flow status implies limited financial flexibility in the short term, requiring external capital sources or cash reserves to sustain operations. Analysis of the three reported margins shows a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, which collectively indicate that the company is not yet profitable and is still incurring losses on its core business activities before accounting for interest and taxes. The balance sheet presents a contrast between total cash of $6.96M and total debt of $417,522, with a Debt to Equity ratio of 6.22, suggesting a highly leveraged capital structure where equity capital is minimal compared to debt obligations. Despite the high leverage, the Current Ratio is 5.68, which indicates strong short-term liquidity as the company holds significantly more current assets than current liabilities. Finally, the Return on Equity is -208.6% and the Return on Assets is -62.9%, metrics that reveal management is currently utilizing shareholder and asset bases to generate negative returns, a typical but risky scenario for pre-commercialization biotech or device companies.
Valuation Assessment
The company's valuation metrics are skewed by its lack of profitability, as the P/E Ratio (TTM) is listed as N/A and the Forward P/E is reported at -2.19. The absence of a trailing P/E and the negative forward multiple imply that traditional earnings-based valuation models are inapplicable, reflecting investor expectations that earnings will eventually turn positive or that the company is valued primarily on its asset base and pipeline potential. The Price to Book ratio is 0.31, which indicates that the market values the company's equity at a significant discount to its book value, suggesting the market perceives the assets or future prospects as worth less than the recorded book value on the balance sheet. While the Price to Sales ratio is N/A and the EV/EBITDA stands at 0.53, these alternative metrics suggest a valuation based on enterprise value relative to earnings before interest, taxes, depreciation, and amortization, though the low EV/EBITDA multiple in a negative earnings environment requires careful interpretation regarding the firm's asset backing. The stock has a 52-Week High of $35.20 and a 52-Week Low of $1.36, providing a wide trading range where the current price sits well below the historical high but significantly above the recent low. The Beta value is 1.65, which explains that the stock's price volatility is substantially higher than the broader market, moving 65% more volatile than the index on average during periods of market fluctuation.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning historical growth rates cannot be calculated to determine if earnings are growing faster or slower than revenue. As the company does not pay a dividend, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the company reinvests all available earnings, or rather, all available cash flow, back into growth initiatives rather than distributing income to shareholders. The lack of a dividend payout ratio confirms that the firm is not currently generating sufficient free cash flow to support shareholder distributions, a standard practice for capital-intensive medical device companies in development. The overall growth and income profile is characterized by a complete absence of dividend income and unquantifiable historical growth rates due to the company's early-stage financial status and lack of reported revenue growth data.